FDA Approves 17th Biosimilar, Third for Herceptin

The US Food and Drug Administration (FDA) on Friday approved Merck and Samsung Bioepis’ Ontruzant (trastuzumab-dttb), the third biosimilar approved in the US to Roche’s Herceptin (trastuzumab).